Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DR-01
- Development stage
- Phase 2
- Lead developer
- Dren Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
DR-01 is a non-fucosylated human immunoglobulin G1 (IgG1) monoclonal antibody that targets CD94, a receptor selectively expressed on cytotoxic terminal effector CD8+ T cells, γδT cells, and natural killer (NK) cells. By binding to CD94, DR-01 leads to rapid depletion of these target cells primarily through antibody-dependent cellular cytotoxicity (ADCC), including fratricide. The drug is being developed by Dren Bio for the treatment of large granular lymphocytic leukemia (LGLL) and various cytotoxic lymphomas—including aggressive NK cell leukemia, cutaneous T-cell lymphoma (CTCL), EBV T-cell lymphoma, hepatosplenic T-cell lymphoma—as well as other related hematologic malignancies. It is currently in Phase 1/2 clinical trials for relapsed or refractory cases of these diseases.
- Other names
- Human anti-CD94 IgG1 monoclonal antibody (non-fucosylated)
02
Targets
KLRD1 (CD94/NKG2A complex)
Beyond the preview
Go deeper on DR-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DR-01.